Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Drug Resistance, Neoplasm"" wg kryterium: Temat


Tytuł:
A combination of stromal PD-L1 and tumoral nuclear β-catenin expression as an indicator of colorectal carcinoma progression and resistance to chemoradiotherapy in locally advanced rectal carcinoma.
Autorzy:
Takahashi H; Department of Pathology, Kitasato University School of Medicine, Sagamihara, Japan.; Department of Pathology, Kitasato University School of Allied Health Science, Sagamihara, Japan.
Watanabe H; Department of Pathology, Kitasato University School of Medicine, Sagamihara, Japan.
Hashimura M; Department of Pathology, Kitasato University School of Medicine, Sagamihara, Japan.
Matsumoto T; Department of Pathology, Kitasato University School of Medicine, Sagamihara, Japan.; Department of Pathology, Kitasato University School of Allied Health Science, Sagamihara, Japan.
Yokoi A; Department of Pathology, Kitasato University School of Medicine, Sagamihara, Japan.
Nakagawa M; Department of Pathology, Kitasato University School of Medicine, Sagamihara, Japan.
Ishibashi Y; Department of Pathology, Kitasato University School of Medicine, Sagamihara, Japan.
Ito T; Department of Pathology, Kitasato University School of Medicine, Sagamihara, Japan.
Ohhigata K; Department of Pathology, Kitasato University School of Medicine, Sagamihara, Japan.
Saegusa M; Department of Pathology, Kitasato University School of Medicine, Sagamihara, Japan.
Pokaż więcej
Źródło:
The journal of pathology. Clinical research [J Pathol Clin Res] 2022 Sep; Vol. 8 (5), pp. 458-469. Date of Electronic Publication: 2022 Jun 27.
Typ publikacji:
Journal Article
MeSH Terms:
B7-H1 Antigen*/genetics
B7-H1 Antigen*/immunology
Drug Resistance, Neoplasm*/genetics
Drug Resistance, Neoplasm*/immunology
Programmed Cell Death 1 Receptor*/genetics
Programmed Cell Death 1 Receptor*/immunology
Radiation Tolerance*/genetics
Radiation Tolerance*/immunology
Rectal Neoplasms*/genetics
Rectal Neoplasms*/immunology
Rectal Neoplasms*/pathology
Rectal Neoplasms*/therapy
beta Catenin*/genetics
beta Catenin*/immunology
Cell Nucleus/genetics ; Cell Nucleus/immunology ; Chemoradiotherapy, Adjuvant ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/immunology ; Colorectal Neoplasms/pathology ; Colorectal Neoplasms/therapy ; Disease Progression ; Gene Expression Regulation, Neoplastic/genetics ; Gene Expression Regulation, Neoplastic/immunology ; Humans ; Neoadjuvant Therapy ; Prognosis ; Tumor Microenvironment/genetics ; Tumor Microenvironment/immunology
Czasopismo naukowe
Tytuł:
Chitosan-Gelatin-EGCG Nanoparticle-Meditated LncRNA TMEM44-AS1 Silencing to Activate the P53 Signaling Pathway for the Synergistic Reversal of 5-FU Resistance in Gastric Cancer.
Autorzy:
Zhou M; Department of Oncology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan road II, Guangzhou, 510080, P. R. China.
Dong J; Department of Oncology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan road II, Guangzhou, 510080, P. R. China.
Huang J; Guangzhou Key Laboratory of Formula-Pattern of Traditional Chinese Medicine, Formula-Pattern Research Center, School of Traditional Chinese Medicine, Jinan University, Guangzhou, 510632, P. R. China.
Ye W; Department of Oncology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan road II, Guangzhou, 510080, P. R. China.
Zheng Z; Department of Oncology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan road II, Guangzhou, 510080, P. R. China.
Huang K; Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan road II, Guangzhou, 510080, P. R. China.
Pan Y; Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan road II, Guangzhou, 510080, P. R. China.
Cen J; Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan road II, Guangzhou, 510080, P. R. China.
Liang Y; Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan road II, Guangzhou, 510080, P. R. China.
Shu G; Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan road II, Guangzhou, 510080, P. R. China.
Ye S; Department of Oncology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan road II, Guangzhou, 510080, P. R. China.
Lu X; Department of Food Science and Engineering, Jinan University, Guangzhou, 510632, P. R. China.
Zhang J; Department of Oncology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan road II, Guangzhou, 510080, P. R. China.
Pokaż więcej
Źródło:
Advanced science (Weinheim, Baden-Wurttemberg, Germany) [Adv Sci (Weinh)] 2022 Aug; Vol. 9 (22), pp. e2105077. Date of Electronic Publication: 2022 Jun 19.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/metabolism
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Drug Resistance, Neoplasm*/drug effects
Drug Resistance, Neoplasm*/genetics
Drug Resistance, Neoplasm*/physiology
Gene Silencing*/drug effects
Gene Silencing*/physiology
Nanoparticles*/therapeutic use
RNA*/genetics
RNA*/metabolism
Stomach Neoplasms*/drug therapy
Stomach Neoplasms*/genetics
Stomach Neoplasms*/metabolism
Animals ; Antimetabolites, Antineoplastic/pharmacology ; Antimetabolites, Antineoplastic/therapeutic use ; Catechin/analogs & derivatives ; Catechin/pharmacology ; Catechin/therapeutic use ; Cell Line, Tumor ; Chitosan/pharmacology ; Chitosan/therapeutic use ; Fluorouracil/pharmacology ; Fluorouracil/therapeutic use ; Gelatin/pharmacology ; Gelatin/therapeutic use ; Gene Expression Regulation, Neoplastic ; Humans ; Intracellular Signaling Peptides and Proteins/genetics ; Intracellular Signaling Peptides and Proteins/metabolism ; Membrane Proteins/genetics ; Membrane Proteins/metabolism ; Mice ; MicroRNAs/genetics ; RNA, Antisense/genetics ; RNA, Antisense/metabolism ; RNA, Long Noncoding/genetics ; RNA, Long Noncoding/metabolism ; Repressor Proteins/genetics ; Repressor Proteins/metabolism ; Signal Transduction/genetics ; Tumor Suppressor Protein p53/genetics ; Tumor Suppressor Protein p53/metabolism
Czasopismo naukowe
Tytuł:
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer.
Autorzy:
Herberts C; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Annala M; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland.
Sipola J; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland.
Ng SWS; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Chen XE; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Nurminen A; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland.
Korhonen OV; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland.
Munzur AD; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Beja K; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Schönlau E; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Bernales CQ; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Ritch E; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Bacon JVW; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Lack NA; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.; School of Medicine, Koç University, Istanbul, Turkey.; Koç University Research Centre for Translational Medicine, Koç University, Istanbul, Turkey.
Nykter M; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland.
Aggarwal R; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Small EJ; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Gleave ME; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Quigley DA; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.; Department of Urology, University of California San Francisco, San Francisco, CA, USA.; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA.
Feng FY; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.; Department of Urology, University of California San Francisco, San Francisco, CA, USA.; Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
Chi KN; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.; Department of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada.
Wyatt AW; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. .; Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia, Canada. .
Pokaż więcej
Corporate Authors:
SU2C/PCF West Coast Prostate Cancer Dream Team
Źródło:
Nature [Nature] 2022 Aug; Vol. 608 (7921), pp. 199-208. Date of Electronic Publication: 2022 Jul 20.
Typ publikacji:
Journal Article
MeSH Terms:
Circulating Tumor DNA*/blood
Circulating Tumor DNA*/genetics
Drug Resistance, Neoplasm*/drug effects
Drug Resistance, Neoplasm*/genetics
Genome, Human*/genetics
Genomics*/methods
High-Throughput Nucleotide Sequencing*
Mutation*
Prostatic Neoplasms*/blood
Prostatic Neoplasms*/drug therapy
Prostatic Neoplasms*/genetics
Prostatic Neoplasms*/pathology
Androgen Receptor Antagonists/pharmacology ; Biomarkers, Tumor/blood ; Biomarkers, Tumor/genetics ; Clone Cells/metabolism ; Clone Cells/pathology ; Disease Progression ; Genetic Markers/genetics ; Humans ; Liquid Biopsy/methods ; Male ; Neoplasm Metastasis/genetics ; Neoplasm Metastasis/pathology ; Nucleosomes/genetics ; Nucleosomes/metabolism ; RNA, Messenger/analysis ; RNA, Messenger/genetics ; RNA, Neoplasm/analysis ; RNA, Neoplasm/genetics ; Receptors, Androgen/metabolism
Czasopismo naukowe
Tytuł:
Microbial metabolite restricts 5-fluorouracil-resistant colonic tumor progression by sensitizing drug transporters via regulation of FOXO3-FOXM1 axis.
Autorzy:
Ghosh S; Department of Microbiology and Immunology, Brown Cancer Center, Center for Microbiomics, Inflammation and Pathogenicity, University of Louisville, Louisville, KY, USA.
Singh R; Department of Microbiology and Immunology, Brown Cancer Center, Center for Microbiomics, Inflammation and Pathogenicity, University of Louisville, Louisville, KY, USA.
Vanwinkle ZM; Department of Microbiology and Immunology, Brown Cancer Center, Center for Microbiomics, Inflammation and Pathogenicity, University of Louisville, Louisville, KY, USA.
Guo H; Department of Radiology, Center for Predictive Medicine, University of Louisville, Louisville, KY, USA.
Vemula PK; Institute for Stem Cell Biology and Regenerative Medicine (inStem), GKVK campus, Bangalore, Karnataka 560065, India.
Goel A; Department of Molecular Diagnostics and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Haribabu B; Department of Microbiology and Immunology, Brown Cancer Center, Center for Microbiomics, Inflammation and Pathogenicity, University of Louisville, Louisville, KY, USA.
Jala VR; Department of Microbiology and Immunology, Brown Cancer Center, Center for Microbiomics, Inflammation and Pathogenicity, University of Louisville, Louisville, KY, USA.
Pokaż więcej
Źródło:
Theranostics [Theranostics] 2022 Jul 18; Vol. 12 (12), pp. 5574-5595. Date of Electronic Publication: 2022 Jul 18 (Print Publication: 2022).
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Colonic Neoplasms*/drug therapy
Colonic Neoplasms*/genetics
Colonic Neoplasms*/metabolism
Colonic Neoplasms*/pathology
Drug Resistance, Neoplasm*/genetics
Drug Resistance, Neoplasm*/physiology
Fluorouracil*/metabolism
Fluorouracil*/pharmacology
Fluorouracil*/therapeutic use
Forkhead Box Protein M1*/genetics
Forkhead Box Protein M1*/metabolism
Forkhead Box Protein O3*/genetics
Forkhead Box Protein O3*/metabolism
Gastrointestinal Microbiome*/genetics
Gastrointestinal Microbiome*/physiology
ATP Binding Cassette Transporter, Subfamily G, Member 2 ; Animals ; Antimetabolites, Antineoplastic/metabolism ; Azoxymethane ; Cell Line, Tumor/drug effects ; Cell Line, Tumor/metabolism ; Coumarins/metabolism ; Humans ; Mice ; Neoplasm Proteins/genetics ; Neoplasm Proteins/metabolism
Czasopismo naukowe
Tytuł:
Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells.
Autorzy:
Prado-Carrillo O; Laboratorio de Fármaco-Oncología, Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Ciudad de Mexico 14080, Mexico.; Posgrado en Ciencias Bioquímicas, Universidad Nacional Autónoma de México (UNAM), Ciudad de Mexico 04510, Mexico.
Arenas-Ramírez A; Laboratorio de Fármaco-Oncología, Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Ciudad de Mexico 14080, Mexico.
Llaguno-Munive M; Laboratorio de Fármaco-Oncología, Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Ciudad de Mexico 14080, Mexico.
Jurado R; Laboratorio de Fármaco-Oncología, Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Ciudad de Mexico 14080, Mexico.
Pérez-Rojas J; Laboratorio de Fármaco-Oncología, Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Ciudad de Mexico 14080, Mexico.
Cervera-Ceballos E; Dirección de Docencia, Instituto Nacional de Cancerología, Ciudad de Mexico 14080, Mexico.
Garcia-Lopez P; Laboratorio de Fármaco-Oncología, Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Ciudad de Mexico 14080, Mexico.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2022 Jul 13; Vol. 23 (14). Date of Electronic Publication: 2022 Jul 13.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/adverse effects
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Drug Resistance, Neoplasm*/drug effects
Drug Resistance, Neoplasm*/genetics
Imatinib Mesylate*/adverse effects
Imatinib Mesylate*/pharmacology
Imatinib Mesylate*/therapeutic use
Ketoconazole*/pharmacology
Ketoconazole*/therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/metabolism
ATP Binding Cassette Transporter, Subfamily B/genetics ; ATP Binding Cassette Transporter, Subfamily B/metabolism ; Apoptosis ; Doxorubicin/pharmacology ; Fusion Proteins, bcr-abl/genetics ; Humans ; K562 Cells ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use
Czasopismo naukowe
Tytuł:
Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP).
Autorzy:
Cardona AF; Direction of Research and Education, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia; Molecular Oncology and Biology Systems Research Group (Fox-G/ONCOLGroup), Universidad El Bosque, Bogotá, Colombia. Electronic address: .
Ruiz-Patiño A; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia; Molecular Oncology and Biology Systems Research Group (Fox-G/ONCOLGroup), Universidad El Bosque, Bogotá, Colombia.
Recondo G; Thoracic Oncology Section, Centro de Educación Médica e Investigaciones Clínicas - CEMIC, Buenos Aires, Argentina.
Martín C; Medical Oncology Department, Thoracic Oncology Section, Instituto Alexander Fleming, Buenos Aires, Argentina.
Raez L; Thoracic Oncology Department, Memorial Cancer Institute, Memorial Health Care System, Miami, FL.
Samtani S; Medical Oncology Department, Bradford Hill Clinical Research Center, Santiago, Chile.
Minata JN; Medical Oncology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Blaquier JB; Medical Oncology Department, Centro de Educación Médica e Investigaciones Clínicas - CEMIC, Buenos Aires, Argentina.
Enrico D; Medical Oncology Department, Thoracic Oncology Section, Instituto Alexander Fleming, Buenos Aires, Argentina.
Burotto M; Medical Oncology Department, Bradfordhill Institute, Santiago, Chile.
Ordóñez-Reyes C; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia; Molecular Oncology and Biology Systems Research Group (Fox-G/ONCOLGroup), Universidad El Bosque, Bogotá, Colombia.
Chamorro DF; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia; Molecular Oncology and Biology Systems Research Group (Fox-G/ONCOLGroup), Universidad El Bosque, Bogotá, Colombia.
Garcia-Robledo JE; Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ.
Corrales L; Clinical Oncology Department, Oncology Unit, Hospital San Juan de Dios/Centro de Investigación y Manejo del Cáncer (CIMCA), San José, Costa Rica.
Zatarain-Barrón ZL; Thoracic Oncology Unit, Instituto Nacional de Cancerología, México City México.
Más L; Medical Oncology Department, Instituto Nacional de Enfermedades Neoplásicas - INEN, Lima, Perú.
Sotelo C; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia; Molecular Oncology and Biology Systems Research Group (Fox-G/ONCOLGroup), Universidad El Bosque, Bogotá, Colombia.
Ricaurte L; Pathology Department, Mayo Clinic, Rochester, MN.
Santoyo N; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia; Molecular Oncology and Biology Systems Research Group (Fox-G/ONCOLGroup), Universidad El Bosque, Bogotá, Colombia.
Cuello M; Clinical Oncology Department, Hospital de Clinicas, Universidad de la Republica - UdeLAR, Montevideo, Uruguay.
Mejía S; Cancer Institute, Las Americas Clinic, Medellin, Colombia.
Jaller E; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia; Molecular Oncology and Biology Systems Research Group (Fox-G/ONCOLGroup), Universidad El Bosque, Bogotá, Colombia.
Vargas C; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia; Molecular Oncology and Biology Systems Research Group (Fox-G/ONCOLGroup), Universidad El Bosque, Bogotá, Colombia; Clinical Oncology Department, Clínica del Country, Bogotá, Colombia.
Carranza H; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia; Molecular Oncology and Biology Systems Research Group (Fox-G/ONCOLGroup), Universidad El Bosque, Bogotá, Colombia; Clinical Oncology Department, Clínica del Country, Bogotá, Colombia.
Otero J; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia; Molecular Oncology and Biology Systems Research Group (Fox-G/ONCOLGroup), Universidad El Bosque, Bogotá, Colombia; Clinical Oncology Department, Clínica del Country, Bogotá, Colombia.
Rodríguez J; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia; Molecular Oncology and Biology Systems Research Group (Fox-G/ONCOLGroup), Universidad El Bosque, Bogotá, Colombia.
Archila P; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia; Molecular Oncology and Biology Systems Research Group (Fox-G/ONCOLGroup), Universidad El Bosque, Bogotá, Colombia.
Bermudez M; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia; Molecular Oncology and Biology Systems Research Group (Fox-G/ONCOLGroup), Universidad El Bosque, Bogotá, Colombia.
Gamez T; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia; Molecular Oncology and Biology Systems Research Group (Fox-G/ONCOLGroup), Universidad El Bosque, Bogotá, Colombia.
Cordeiro de Lima V; Medical Oncology Department, A.C.Camargo Cancer Center, Sao Paulo, Brazil.
Freitas H; Medical Oncology Department, A.C.Camargo Cancer Center, Sao Paulo, Brazil.
Russo A; Medical Oncology Unit, A.O. Papardo, Messina, Italy.
Polo C; Clinical Oncology Department, Instituto Nacional de Cancerología - INC, Bogotá, Colombia.
Malapelle U; Department of Public Health, University Federico II, Naples, Italy.
Perez DM; Center for Thoracic Oncology, The Tisch Cancer Institute Icahn School of Medicine, Mount Sinai, Mount Sinai Health System, One Gustave Levy Place, NY.
Rolfo C; Center for Thoracic Oncology, The Tisch Cancer Institute Icahn School of Medicine, Mount Sinai, Mount Sinai Health System, One Gustave Levy Place, NY.
Viola L; Thoracic Oncology Unit, Fundación Neumológica Colombiana, Bogotá, Colombia.
Rosell R; Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Barcelona, Spain.
Arrieta O; Thoracic Oncology Unit, Instituto Nacional de Cancerología, México City México.
Pokaż więcej
Źródło:
Clinical lung cancer [Clin Lung Cancer] 2022 Sep; Vol. 23 (6), pp. 522-531. Date of Electronic Publication: 2022 Jun 06.
Typ publikacji:
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/pathology
Drug Resistance, Neoplasm*
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
Acrylamides ; Aniline Compounds ; Disease Progression ; ErbB Receptors/genetics ; Hispanic or Latino ; Humans ; Indoles ; Liver Neoplasms/drug therapy ; Liver Neoplasms/secondary ; Middle Aged ; Mutation/genetics ; Neoplasm Recurrence, Local/drug therapy ; Protein Kinase Inhibitors/pharmacology ; Pyrimidines ; Retrospective Studies
Czasopismo naukowe
Tytuł:
S6K1 amplification confers innate resistance to CDK4/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancer.
Autorzy:
Mo H; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Liu X; Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Xue Y; Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.; State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Chen H; State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Guo S; State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Li Z; State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Wang S; Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Li C; State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Han J; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Fu M; State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Song Y; State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Li D; State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China. .
Ma F; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China. .
Pokaż więcej
Źródło:
Molecular cancer [Mol Cancer] 2022 Aug 30; Vol. 21 (1), pp. 171. Date of Electronic Publication: 2022 Aug 30.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/drug therapy
Breast Neoplasms*/genetics
Drug Resistance, Neoplasm*/genetics
Protein Kinase Inhibitors*/therapeutic use
Ribosomal Protein S6 Kinases, 70-kDa*/genetics
Animals ; Cell Line, Tumor ; Circulating Tumor DNA ; Cyclin-Dependent Kinase 4/antagonists & inhibitors ; Cyclin-Dependent Kinase 6/antagonists & inhibitors ; Female ; Humans ; Neoplasm Recurrence, Local ; Proto-Oncogene Proteins c-myc ; Receptors, Estrogen/genetics
Czasopismo naukowe
Tytuł:
Designing Novel BCR-ABL Inhibitors for Chronic Myeloid Leukemia with Improved Cardiac Safety.
Autorzy:
Pandrala M; Department of Cell, Developmental and Cancer Biology, Center for Experimental Therapeutics, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon 97201, United States.
Bruyneel AAN; Cardiovascular Institute and Department of Medicine, Stanford University, Stanford, California 94305, United States.
Hnatiuk AP; Cardiovascular Institute and Department of Medicine, Stanford University, Stanford, California 94305, United States.
Mercola M; Cardiovascular Institute and Department of Medicine, Stanford University, Stanford, California 94305, United States.
Malhotra SV; Department of Cell, Developmental and Cancer Biology, Center for Experimental Therapeutics, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon 97201, United States.
Pokaż więcej
Źródło:
Journal of medicinal chemistry [J Med Chem] 2022 Aug 25; Vol. 65 (16), pp. 10898-10919. Date of Electronic Publication: 2022 Aug 09.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Drug Resistance, Neoplasm*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy
Cell Line, Tumor ; Fusion Proteins, bcr-abl ; Humans ; Mutation ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use
Czasopismo naukowe
Tytuł:
Purinergic receptors are a key bottleneck in tumor metabolic reprogramming: The prime suspect in cancer therapeutic resistance.
Autorzy:
Aria H; Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.; Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Rezaei M; Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Nazem S; Department of Laboratory Medicine, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Daraei A; Department of Medical Genetics, School of Medicine, Babol University of Medical Sciences, Babol, Iran.
Nikfar G; Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.
Mansoori B; Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.
Bahmanyar M; Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.
Tavassoli A; Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.
Vakil MK; Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.
Mansoori Y; Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.; Department of Medical Genetics, Fasa University of Medical Sciences, Fasa, Iran.
Pokaż więcej
Źródło:
Frontiers in immunology [Front Immunol] 2022 Aug 22; Vol. 13, pp. 947885. Date of Electronic Publication: 2022 Aug 22 (Print Publication: 2022).
Typ publikacji:
Journal Article; Review
MeSH Terms:
Drug Resistance, Neoplasm*
Neoplasms*/metabolism
Neoplasms*/therapy
Adenosine Triphosphate/metabolism ; Humans ; Receptors, Purinergic/metabolism ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
KDELR3 Is a Prognostic Biomarker Related to the Immune Infiltration and Chemoresistance of Anticancer Drugs in Uveal Melanoma.
Autorzy:
Zhang J; Department of Pharmacy, Linyi Central Hospital, Linyi, Shandong, China.
Zhang J; Department of Traditional Chinese Medicine, Qingdao Eighth People's Hospital, Qingdao, Shandong, China.
Guan J; Department of Traditional Chinese Medicine, Qingdao Eighth People's Hospital, Qingdao, Shandong, China.
Yu L; Department of Traditional Chinese Medicine, Qingdao Eighth People's Hospital, Qingdao, Shandong, China.
Yan S; Department of Cataract, Jinan Aier Eye Hospital, Jinan, Shandong, China.
Pokaż więcej
Źródło:
Disease markers [Dis Markers] 2022 Aug 21; Vol. 2022, pp. 1930185. Date of Electronic Publication: 2022 Aug 21 (Print Publication: 2022).
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Drug Resistance, Neoplasm*/genetics
Adult ; Biomarkers, Tumor/metabolism ; Humans ; Melanoma ; Prognosis ; Uveal Neoplasms
SCR Disease Name:
Uveal melanoma
Czasopismo naukowe
Tytuł:
MYBL1 induces transcriptional activation of ANGPT2 to promote tumor angiogenesis and confer sorafenib resistance in human hepatocellular carcinoma.
Autorzy:
Zhu J; Guangdong Province Key Laboratory for Biotechnology Drug Candidates, School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, China.
Wu Y; Guangdong Province Key Laboratory for Biotechnology Drug Candidates, School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, China.
Yu Y; Department of Cardiothoracic Surgery, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Taizhou, China.
Li Y; Guangdong Province Key Laboratory for Biotechnology Drug Candidates, School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, China.
Shen J; Department of Cardiothoracic Surgery, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Taizhou, China. .
Zhang R; Guangdong Province Key Laboratory for Biotechnology Drug Candidates, School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, China. .
Pokaż więcej
Źródło:
Cell death & disease [Cell Death Dis] 2022 Aug 20; Vol. 13 (8), pp. 727. Date of Electronic Publication: 2022 Aug 20.
Typ publikacji:
Journal Article
MeSH Terms:
Angiopoietin-2*/genetics
Angiopoietin-2*/metabolism
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/genetics
Carcinoma, Hepatocellular*/metabolism
Drug Resistance, Neoplasm*/genetics
Liver Neoplasms*/drug therapy
Liver Neoplasms*/genetics
Liver Neoplasms*/metabolism
Proto-Oncogene Proteins*/metabolism
Trans-Activators*/metabolism
Adaptor Proteins, Signal Transducing/metabolism ; Cell Line, Tumor ; Cell Proliferation ; Gene Expression Regulation, Neoplastic ; Humans ; Intracellular Signaling Peptides and Proteins ; Neovascularization, Pathologic/drug therapy ; Neovascularization, Pathologic/genetics ; Protein-Arginine N-Methyltransferases/metabolism ; Sorafenib/pharmacology ; Sorafenib/therapeutic use ; Transcriptional Activation
Czasopismo naukowe
Tytuł:
SND1 confers chemoresistance to cisplatin-induced apoptosis by targeting GAS6-AKT in SKOV3 ovarian cancer cells.
Autorzy:
Ha C; Department of Biochemistry and Molecular Biology, Department of Immunology, School of Basic Medical Science, Tianjin Medical University, Tianjin, 300070, China.
Hu L; Department of Biochemistry and Molecular Biology, Department of Immunology, School of Basic Medical Science, Tianjin Medical University, Tianjin, 300070, China.
Ren Y; Department of Biochemistry and Molecular Biology, Department of Immunology, School of Basic Medical Science, Tianjin Medical University, Tianjin, 300070, China.
Yang J; Department of Biochemistry and Molecular Biology, Department of Immunology, School of Basic Medical Science, Tianjin Medical University, Tianjin, 300070, China.; Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Key Laboratory of Cellular and Molecular Immunology in Tianjin, Excellent Talent Project, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Tianjin Medical University, Tianjin, China.
Xin L; Department of Biochemistry and Molecular Biology, Department of Immunology, School of Basic Medical Science, Tianjin Medical University, Tianjin, 300070, China. .; Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Key Laboratory of Cellular and Molecular Immunology in Tianjin, Excellent Talent Project, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Tianjin Medical University, Tianjin, China. .
Pokaż więcej
Źródło:
Medical oncology (Northwood, London, England) [Med Oncol] 2022 Aug 16; Vol. 39 (11), pp. 169. Date of Electronic Publication: 2022 Aug 16.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/pharmacology
Cisplatin*/pharmacology
Drug Resistance, Neoplasm*/genetics
Endonucleases*/genetics
Ovarian Neoplasms*/drug therapy
Ovarian Neoplasms*/genetics
Ovarian Neoplasms*/metabolism
Apoptosis ; Cell Line, Tumor ; Cell Proliferation ; Female ; Humans ; Intercellular Signaling Peptides and Proteins/metabolism ; Proto-Oncogene Proteins c-akt/metabolism
Czasopismo naukowe
Tytuł:
Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors.
Autorzy:
Reinbold R; Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, 12 Mansfield, Oxford, OX1 3TA, UK.
Hvinden IC; Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, 12 Mansfield, Oxford, OX1 3TA, UK.
Rabe P; Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, 12 Mansfield, Oxford, OX1 3TA, UK.
Herold RA; Department of Chemistry, University of Oxford, Oxford, OX1 3QR, UK.
Finch A; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
Wood J; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.; Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
Morgan M; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.; Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
Staudt M; Institute of Pharmaceutical Sciences, University of Freiburg, 79104, Freiburg, Germany.
Clifton IJ; Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, 12 Mansfield, Oxford, OX1 3TA, UK.
Armstrong FA; Department of Chemistry, University of Oxford, Oxford, OX1 3QR, UK.
McCullagh JSO; Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, 12 Mansfield, Oxford, OX1 3TA, UK.
Redmond J; GlaxoSmithKline, Gunnels Wood Rd, Stevenage, SG1 2NY, UK.
Bardella C; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
Abboud MI; Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, 12 Mansfield, Oxford, OX1 3TA, UK. .; Department of Natural Sciences, Lebanese American University, Byblos/Beirut, Lebanon. .
Schofield CJ; Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, 12 Mansfield, Oxford, OX1 3TA, UK. .
Pokaż więcej
Źródło:
Nature communications [Nat Commun] 2022 Aug 15; Vol. 13 (1), pp. 4785. Date of Electronic Publication: 2022 Aug 15.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Drug Resistance, Neoplasm*/genetics
Isocitrate Dehydrogenase*/antagonists & inhibitors
Isocitrate Dehydrogenase*/genetics
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Glycine/analogs & derivatives ; Glycine/therapeutic use ; Humans ; Mutation ; Pyridines/therapeutic use
Czasopismo naukowe
Tytuł:
Selenium Yeast and Fish Oil Combination Diminishes Cancer Stem Cell Traits and Reverses Cisplatin Resistance in A549 Sphere Cells.
Autorzy:
Lai IC; The Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 11031, Taiwan.; Division of Radiation Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei 11217, Taiwan.; School of Medicine, National Yang Ming Chiao Tung University, Taipei 11230, Taiwan.
Liao CH; Cancer Center, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan.
Hu MH; Cancer Center, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan.; Division of Hematology and Medical Oncology, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan.
Chang CL; Cancer Center, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan.; Division of Hematology and Medical Oncology, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan.; Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.
Lai GM; Cancer Center, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan.; Division of Hematology and Medical Oncology, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan.
Chiou TJ; Cancer Center, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan.; Division of Hematology and Medical Oncology, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan.
Hsia S; Taiwan Nutraceutical Association, Taipei 10596, Taiwan.
Tsai WL; Cancer Center, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan.
Lin YY; Cancer Center, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan.
Chuang SE; National Institute of Cancer Research, National Health Research Institutes, Miaoli 35053, Taiwan.
Whang-Peng J; Cancer Center, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan.; Division of Hematology and Medical Oncology, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan.
Chen HY; The Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 11031, Taiwan.; Ph.D. Program for Translational Medicine, National Taiwan University, Taipei 10051, Taiwan.; Genome and Systems Biology Degree Program, National Taiwan University, Taipei 10051, Taiwan.; Ph.D. Program in Microbial Genomics, National Chung Hsing University, Taichung 40227, Taiwan.; Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung 80761, Taiwan.; Institute of Statistical Science, Academia Sinica, Taipei 11529, Taiwan.
Yao CJ; Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.; Department of Medical Education and Research, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan.
Pokaż więcej
Źródło:
Nutrients [Nutrients] 2022 Aug 07; Vol. 14 (15). Date of Electronic Publication: 2022 Aug 07.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/adverse effects
Antineoplastic Agents*/metabolism
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/metabolism
Cisplatin*/pharmacology
Drug Resistance, Neoplasm*/drug effects
Lung Neoplasms*/drug therapy
Lung Neoplasms*/metabolism
A549 Cells/drug effects ; A549 Cells/metabolism ; AMP-Activated Protein Kinases/metabolism ; Cell Line, Tumor ; Cell Proliferation ; Fish Oils/metabolism ; Fish Oils/pharmacology ; Humans ; Neoplastic Stem Cells ; Phenotype ; Saccharomyces cerevisiae/metabolism ; Selenium/metabolism ; Selenium/pharmacology
Czasopismo naukowe
Tytuł:
Autophagy in acute myeloid leukemia: a paradoxical role in chemoresistance.
Autorzy:
Khan A; Room No. 239, Laboratory Oncology Unit, Dr BRA IRCH, All India Institute of Medical Sciences, New Delhi, India.
Singh VK; Room No. 239, Laboratory Oncology Unit, Dr BRA IRCH, All India Institute of Medical Sciences, New Delhi, India.
Thakral D; Room No. 239, Laboratory Oncology Unit, Dr BRA IRCH, All India Institute of Medical Sciences, New Delhi, India.
Gupta R; Room No. 239, Laboratory Oncology Unit, Dr BRA IRCH, All India Institute of Medical Sciences, New Delhi, India. .
Pokaż więcej
Źródło:
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2022 Aug; Vol. 24 (8), pp. 1459-1469. Date of Electronic Publication: 2022 Feb 26.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Drug Resistance, Neoplasm*
Leukemia, Myeloid, Acute*/genetics
Autophagy ; Humans
Czasopismo naukowe
Tytuł:
Hsa_circ_0074269-mediated Upregulation of TUFT1 Through miR-485-5p Increases Cisplatin Resistance in Cervical Cancer.
Autorzy:
Chen J; Department of Pathology, Jingjiang People's Hospital, Taizhou City, 214500, Jiangsu, China.
Wu S; Department of Pathology, Jingjiang People's Hospital, Taizhou City, 214500, Jiangsu, China.
Wang J; Department of Pathology, Jingjiang People's Hospital, Taizhou City, 214500, Jiangsu, China.
Sha Y; Department of Pathology, Jingjiang People's Hospital, Taizhou City, 214500, Jiangsu, China.
Ji Y; Department of General Surgery, Jingjiang People's Hospital, No.9-5, Kejixincun, Jingjiang, Taizhou City, 214500, Jiangsu Province, China. .
Pokaż więcej
Źródło:
Reproductive sciences (Thousand Oaks, Calif.) [Reprod Sci] 2022 Aug; Vol. 29 (8), pp. 2236-2250. Date of Electronic Publication: 2022 Jan 24.
Typ publikacji:
Journal Article
MeSH Terms:
Cisplatin*/pharmacology
Dental Enamel Proteins*/genetics
Drug Resistance, Neoplasm*/genetics
MicroRNAs*/genetics
RNA, Circular*/genetics
Uterine Cervical Neoplasms*/drug therapy
Uterine Cervical Neoplasms*/genetics
Animals ; Cell Line, Tumor ; Cell Proliferation ; Female ; Humans ; Up-Regulation
Czasopismo naukowe
Tytuł:
lncRNA XLOC013218 promotes cell proliferation and TMZ resistance by targeting the PIK3R2-mediated PI3K/AKT pathway in glioma.
Autorzy:
Zhou J; Department of Neurosurgery Center, The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China on Diagnosis and Treatment of Cerebrovascular Disease, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, The Neurosurgery Institute of Guangdong Province, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Xu N; Department of Neurosurgery Center, The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China on Diagnosis and Treatment of Cerebrovascular Disease, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, The Neurosurgery Institute of Guangdong Province, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Liu B; Department of Neurosurgery Center, The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China on Diagnosis and Treatment of Cerebrovascular Disease, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, The Neurosurgery Institute of Guangdong Province, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Wang C; Department of Neurosurgery Center, The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China on Diagnosis and Treatment of Cerebrovascular Disease, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, The Neurosurgery Institute of Guangdong Province, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
He Z; Department of Neurosurgery, The Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou, China.
Lenahan C; Department of Biomedical Sciences, Burrell College of Osteopathic Medicine, Las Cruces, New Mexico, USA.
Tang W; Department of Neurosurgery Center, The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China on Diagnosis and Treatment of Cerebrovascular Disease, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, The Neurosurgery Institute of Guangdong Province, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Zeng H; Department of Neurosurgery Center, The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China on Diagnosis and Treatment of Cerebrovascular Disease, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, The Neurosurgery Institute of Guangdong Province, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Guo H; Department of Neurosurgery Center, The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China on Diagnosis and Treatment of Cerebrovascular Disease, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, The Neurosurgery Institute of Guangdong Province, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Pokaż więcej
Źródło:
Cancer science [Cancer Sci] 2022 Aug; Vol. 113 (8), pp. 2681-2692. Date of Electronic Publication: 2022 Jun 14.
Typ publikacji:
Journal Article
MeSH Terms:
Brain Neoplasms*/drug therapy
Brain Neoplasms*/genetics
Drug Resistance, Neoplasm*/genetics
Glioblastoma*/drug therapy
Glioblastoma*/genetics
Glioma*/drug therapy
Glioma*/genetics
Phosphatidylinositol 3-Kinases*/genetics
Phosphatidylinositol 3-Kinases*/metabolism
RNA, Long Noncoding*/genetics
Cell Line, Tumor ; Cell Proliferation/genetics ; Gene Expression Regulation, Neoplastic ; Humans ; Proto-Oncogene Proteins c-akt/metabolism ; Temozolomide/pharmacology ; Transcription Factors/genetics
Czasopismo naukowe
Tytuł:
PEAK1 promotes invasion and metastasis and confers drug resistance in breast cancer.
Autorzy:
Wang X; Department of Breast Surgery, The Affiliated Hospital of Qingdao University, Qingdao, 266003, Shandong, China.
Zheng Y; Department of Operating Room, The Affiliated Hospital of Qingdao University, Qingdao, 266003, Shandong, China.
Wang Y; Department of Breast Surgery, The Affiliated Hospital of Qingdao University, Qingdao, 266003, Shandong, China. .
Pokaż więcej
Źródło:
Clinical and experimental medicine [Clin Exp Med] 2022 Aug; Vol. 22 (3), pp. 393-402. Date of Electronic Publication: 2021 Sep 23.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/drug therapy
Breast Neoplasms*/pathology
Drug Resistance, Neoplasm*
Protein-Tyrosine Kinases*/metabolism
Cell Line, Tumor ; Cell Movement ; Cell Proliferation ; Doxorubicin/pharmacology ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; MCF-7 Cells ; Neoplasm Metastasis ; Pseudopodia/metabolism ; Signal Transduction
Czasopismo naukowe
Tytuł:
Study on the Mechanism of Action of STAT3 in the Drug Resistance of Gastric Cancer Cells.
Autorzy:
Di J; Department of Medical Oncology, Affiliated Hospital of Qinghai University, XiNing 810012, China.; School of Clinical Medicine, Tsinghua University, Beijing 100084, China.
Jiang B; School of Clinical Medicine, Tsinghua University, Beijing 100084, China.; Beijing Tsinghua Changgung Hospital, Beijing 100084, China.
Shang H; Department of General Surgery, The Second Affiliated Hospital, Xi'an Jiaotong University School of Medicine, Xi'an, Shaanxi 710004, China.
Yang X; Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, China.
Zhang C; Department of Surgical Oncology, Affiliated Hospital of Qinghai University, XiNing 810012, China.
Shi X; Department of Anesthesiology and Surgery, The Second Affiliated Hospital, Xi'an Jiaotong University School of Medicine, Xi'an, Shaanxi 710004, China.
Chai Y; School of Clinical Medicine, Tsinghua University, Beijing 100084, China.
Pokaż więcej
Źródło:
Contrast media & molecular imaging [Contrast Media Mol Imaging] 2022 Jul 30; Vol. 2022, pp. 1426343. Date of Electronic Publication: 2022 Jul 30 (Print Publication: 2022).
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/adverse effects
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Cisplatin*/adverse effects
Cisplatin*/pharmacology
Cisplatin*/therapeutic use
Drug Resistance, Neoplasm*/genetics
STAT3 Transcription Factor*/genetics
STAT3 Transcription Factor*/metabolism
Stomach Neoplasms*/drug therapy
Stomach Neoplasms*/genetics
Stomach Neoplasms*/metabolism
Stomach Neoplasms*/pathology
Apoptosis ; Cell Line, Tumor ; Humans
Czasopismo naukowe
Tytuł:
Mechanism-based design of agents that selectively target drug-resistant glioma.
Autorzy:
Lin K; Department of Chemistry, Yale University, New Haven, CT 06520, USA.; Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT 06520, USA.; Department of Pathology, Yale School of Medicine, New Haven, CT 06520, USA.
Gueble SE; Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT 06520, USA.
Sundaram RK; Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT 06520, USA.
Huseman ED; Department of Chemistry, Yale University, New Haven, CT 06520, USA.
Bindra RS; Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT 06520, USA.; Department of Pathology, Yale School of Medicine, New Haven, CT 06520, USA.
Herzon SB; Department of Chemistry, Yale University, New Haven, CT 06520, USA.; Department of Pharmacology, Yale School of Medicine, New Haven, CT 06520, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2022 Jul 29; Vol. 377 (6605), pp. 502-511. Date of Electronic Publication: 2022 Jul 28.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents, Alkylating*/chemistry
Antineoplastic Agents, Alkylating*/pharmacology
Antineoplastic Agents, Alkylating*/therapeutic use
Brain Neoplasms*/drug therapy
Brain Neoplasms*/genetics
DNA Modification Methylases*/genetics
DNA Repair Enzymes*/genetics
Drug Design*
Drug Resistance, Neoplasm*/genetics
Glioblastoma*/drug therapy
Glioblastoma*/genetics
Tumor Suppressor Proteins*/genetics
Cell Line, Tumor ; DNA Methylation/genetics ; DNA Repair/genetics ; Dacarbazine/pharmacology ; Dacarbazine/therapeutic use ; Humans ; Temozolomide/pharmacology ; Temozolomide/therapeutic use
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies

Prześlij opinię

Twoje opinie są dla nas bardzo ważne i mogą być niezwykle pomocne w pokazaniu nam, gdzie możemy dokonać ulepszeń. Bylibyśmy bardzo wdzięczni za poświęcenie kilku chwil na wypełnienie krótkiego formularza.

Formularz